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Recent studies demonstrate that immunoglobulin A (IgA), the most abundant antibody secreted 
at mucosal surfaces, is critical for limiting chronic inflammation but the mechanism by which this 
occurs is undefined. Regulation of the composition of the commensal bacterial community in the 
gut (i.e. the microbiota) could be one mechanism. IgA can be produced through T-cell-dependent 
(TD) and T-cell-independent (TiD) pathways. While TiD IgA is the most abundant IgA secreted 
into the gut, the relative contribution of TD and TiD IgA in regulating microbiota composition is 
controversial. Antigen presentation by B cells to T cells is essential for TD responses, and this is 
carried out by MHC class II molecules. Here, we sought to address the hypothesis that B-cell-
intrinsic MHCII antigen presentation promotes anti-commensal TD IgA responses that influence 
microbiota composition. In order to do this, RAG1-/- mice, that lack their own T and B cells, 
received adoptive transfers of wildtype (WT) T cells along with MHCII-positive (MHCII+) B cells, 
or WT T cells along with MHCII-deficient (MHCII-) B cells. Results of our experiments demonstrate 
that the presence of MHCII on B cells leads to higher levels of IgA secretion into the gut, is critical 
to the formation of germinal centers, enhances binding of gut bacteria by high-affinity IgA, and is 
associated with greater species richness in the gut microbial community. Our results support that 








 Since Kircher’s discovery of microorganisms in 1646, scientists have been curious about 
their biological relationships with humans [1]. Kircher speculated that agents he observed via 
microscopy in the blood of sick individuals were living organisms which could cause disease. Over 
the next several centuries, this concept, known as germ theory, gained significant support in the 
scientific community through the works of physicians like Semmelweis and Pasteur, who 
conducted experiments to describe the behaviors of the “animalicules” discovered by their 
predecessors and to connect them to infectious disease [2, 3].  By the late nineteenth century, 
microorganisms were generally accepted to be the causative agents of infection. However, 
scientists also observed that healthy individuals harbor microorganisms as well – for example, 
Koch discovered that some humans carry Vibrio cholerae, the bacteria responsible for cholera, 
and are entirely asymptomatic of the disease [4]. Metchnikoff was perhaps the first to describe 
the positive effects of what modern scientists call the microbiota – the community of microbes 
which reside on environmentally exposed surfaces of an animal. He wrote that there are “many 
useful microbes” and recommended the consumption of sour milk products cultured with Bacillus 
bulgaricus [5]. He believed the bacteria would propagate in an individual’s gut and prolong one’s 
lifespan through its secretion of lactic acid, which he believed could modulate the composition of 
the gut microbiota.  Indeed, scientists have since confirmed that the composition of the human 
gut microbiota is vitally important to health and wellness and governed by a variety of factors.   
 The makeup of the microbiome has been shown to be responsive to variables like sex, 
age, diet, exercise levels, infection, and pharmacological treatment. Healthy gut microbiota are 
frequently characterized by high levels of diversity in species, and lack of diversity is correlated 
with dysbiosis – pathogenic effects caused by alterations to microbiota composition and/or 
function [6]. Gut dysbiosis has now been linked to numerous human diseases. Recent studies 
have revealed that gut dysbiosis is correlated not only with conditions that effect the bowels, like 
Crohn’s disease and ulcerative colitis, but also with obesity, psychiatric disorders like Alzheimer’s 
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and schizophrenia, liver disease, and a wide variety of others [7]. In light of these discoveries, it 
has become increasingly clear that it is important to elucidate the mechanisms through which the 
microbiome is regulated. 
The immune system plays a crucial role in maintaining homeostasis and promoting 
diversity in the mammalian gut [8]. Because of the unique qualities of the gut environment, the 
mucosal immune system, which maintains gut homeostasis, is also unique. The intestine is filled 
with a plethora of harmless antigens from food and commensal bacteria, but also can contain 
pathogenic bacteria. In order to mediate this environment, the intestinal lumen is shielded from 
the lamina propria and deeper host tissues by a layer of mucous and epithelial cells [9]. One 
particularly important aspect of the interactions between the immune system and the bacteria of 
the gut is the secretion of antibodies into the intestine by terminally differentiated B cells (i.e. 
plasma cells). Antibody production in the intestine is stimulated through the uptake of antigens 
through the epithelial cells of the gut, most specifically through microfold cells (i.e. M cells) [10]. 
These cells selectively endocytose antigens and transport them to the basal side of the 
epithelium, presenting them to dendritic cells. These antigens are transferred to antigen-
presenting dendritic cells, which transfer them to B cells in Peyer’s patches and other gut-
associated lymphoid tissues, who receive them via the B cell receptor. Subsequently, B cells 
endocytose these antigens, process them, and present them on their surfaces via major 
histocompatibility class II (MHCII) molecules. These cells subsequently move to the lymphoid 
follicles, where antigens are then presented to T follicular helper cells (TFH), who, in tandem with 
B cells, form a germinal center and stimulate the proliferation of antibody-producing plasma cells 
which subsequently secrete antibodies [10].  
Immunoglobulin A (IgA) is the most abundantly secreted antibody on mucosal surfaces 
and plays an important role in maintaining healthy bacterial diversity in the gut. It has been shown 
to coat up to 75% of all bacteria in the gut [11]. Despite being the most abundant immunoglobulin, 
IgA had long been considered to be an unimportant aspect of the adaptive immune response. 
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This belief was largely held due to the relatively mild phenotypes previously associated with 
selective IgA deficiency in humans. In recent times, we have learned that IgA can be critical to 
host health. IgA deficiency is the most common primary (i.e. heritable) antibody deficiency, and 
the presentation of this condition is highly variable between individuals. Clinically, IgA deficiency 
can go unnoticed, as screening for this antibody is not common in practice. However, studies 
which follow IgA-deficient patients longitudinally demonstrate that they are commonly affected by 
related ailments. Frequently, IgA-deficient subjects develop infections and suffer from food 
allergies. Less frequently, patients can develop asthma, skin infections, and even autoimmune 
diseases [12]. IgA-deficiency and food allergy are frequently linked together in literature, which 
leads scientists to question which mechanisms cause this connection to occur [13]. Food 
allergies, like many of the pathologies associated with antibody deficiency have been associated 
with gut dysbiosis and subsequent inflammatory responses. In order to understand this 
connection, we need to consider the mechanisms through which IgA is able to promote 
homeostasis and provide protection from pathogenic bacteria and potentially harmful antigens. 
IgA is secreted in a dimerized form and can attach to bacterial cells via both its binding 
domains and through glycosylated side chains [14]. Generally, IgA binding mechanisms in the gut 
can be categorized into two types of activities – those that encourage commensal bacteria to 
proliferate, and those that protect the host from antigens and pathogenic bacteria. Immune 
exclusion is an important mechanism by which IgA protects host tissues. Immune exclusion is a 
process whereby antibodies physically block the interaction between microbes (or their harmful 
products) and host tissues. For example, it has been shown in mice that nonspecific IgA binding 
is sufficient to prevent the attachment of cholera toxin to the epithelium of the gut which protects 
animals from disease [15].  Toxins are then trapped in the mucosa or excreted and cannot cause 
harm to the intestinal barrier. This is also the mechanism frequently implicated in this antibodies’ 
protection of the host against food allergens – through binding to these substances, the antibody 
can prevent them from entering the lamina propria, where they might encourage an inflammatory 
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response [13]. Additionally, it has been shown that bacterial cells coated with IgA are susceptible 
to agglutination, where these cells clump together in mechanisms spurred on by antibody binding 
and lose their propensity to bind to the cellular membranes of the gut and are also far less motile. 
One important aspect of this process is entrapment of bacteria in the mucosal lining which coats 
the apical side of the intestinal epithelium. Because IgA is heavily glycosylated, it concentrates in 
the mucus further aiding in entrapment of bacteria in the mucus. Entrapment prevents pathogenic 
microorganisms from transcending the mucosa and colonizing the submucosa. Interestingly, 
pathogenic bacteria have been shown to be much less prone to replication after IgA attachment, 
showing that the antibody can root out potential challenges to the homeostasis of the microbiota 
composition by quenching virulence. For example, in studies done with Shigella flexneri, IgA 
binding to the O antigen (a major virulence factor) prevented the bacteria from binding to epithelial 
cells and decreased membrane potential, indicating that IgA can directly inhibit bacterial virulence 
[16]. Additionally, secretory IgA is capable of limiting the pro-inflammatory effects of luminal 
microbes when they do colonize the mucus lining. For example, in rabbit models, it was 
demonstrated that IgA has a vital role in preventing S. flexneri from upregulating inflammatory 
genes in immune cells of the Peyer’s patches (lymphoid tissues embedded in the wall of the small 
intestines of mammals) [17].  
In addition to its protective properties, IgA promotes the proliferation of beneficial bacteria 
and encourages diversity. Bacteroides fragilis, a commensal bacterium in the gut, is demonstrated 
to utilize IgA binding in order to adhere to the mucosal epithelium in the gut, which is a niche in 
which it thrives. In this instance, IgA binding to carbohydrates on the cellular surface of B. fragilis 
encourages the antibody-coated bacteria to associate closely with the epithelial cells and mucous 
membranes of the intestine, and aggregate in this ecosystem. Donaldson et al. demonstrated that 
in IgA-/- mice, the Bacteroides family was unable to colonize the lamina propria [18]. In mice, it 
has been shown that the composition of the microbiota changes from a proinflammatory 
“immature” to anti-inflammatory “mature” state over time. Using a RAG-/- model, it was 
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demonstrated that mice lacking an IgA targeted response against -proteobacteria, specifically 
Enterbacteriaceae, had high levels of colonic inflammation as compared to IgA-producing mice 
[19]. IgA-producing wild-type mice had higher levels of bacterial diversity in the microbiota and 
the community was not dominated by proinflammatory species, in contrast to the experimental 
group that lacked IgA production. This demonstrates the vital role of IgA in promoting the diversity 
of the microbiome through suppression of harmful bacteria, thereby giving helpful commensals 
an opportunity to proliferate. Additionally, it has recently been suggested that IgA binding can 
induce direct regulatory effects on genes in commensal bacteria. In studies done focusing on the 
model commensal bacteria Bacteroides thetaiotamicron, it has been shown that IgA binding 
upregulates the production of MAFF (mucus-associated functional factor). The downstream 
effects of this upregulation are intriguing; production of MAFF by B. thetaiotamicron results in 
larger bacterial cells and increases their growth rate. B.thetaiotamicron-produced MAFF also 
promotes the growth of groups of bacteria within the genus Clostridium. Interestingly, the 
upregulation of MAFF also increases epithelial cell proliferation in the intestine, which enhances 
gut barrier function and further protects the host [20].  
 MHCII molecules are of particular interest due to their importance in shaping adaptive 
immune responses and the fact that they are some of the most genetically polymorphic genes 
found in vertebrates. MHCII molecules are glycoproteins that bind protein (i.e. peptide) antigens 
and present them on the cell surface where they can stimulate T cell activation. B cells express 
MHCII, and the interaction with T cells is central to the development of TD IgA response [21]. In 
the TD pathway of B-cell activation (the focus of this paper) antigen-presenting cells (APCs), 
which include B cells, utilize MHCII to present antigens to T cells. These MHCII:peptide 
complexes stimulate T cells via their T cell receptor (TCR). This causes T cell activation and 
subsequent crosstalk between T cells and B cells that ultimately results in the maturation of B 
cells into plasma cells that secrete antibodies. The importance of this response as compared to 
the TiD pathway of B cell activation lies in the specificity of antibodies produced through each 
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pathway. In several ways, it has been demonstrated that specific IgA responses do have a role in 
modulating the microbiota. For example, Kawamoto et al. demonstrated that T-cell transfer into 
T-cell deficient mice, thereby allowing for TFH cell proliferation and TD B cell activation, was 
associated with enhanced species diversity within gut microbial communities [22]. Several papers 
also describe the importance of MHCII on group 3 innate lymphoid cells (ILC3) in controlling the 
composition of the gut microbiota via regulation of CD4+ T cell activation and the magnitude of 
the ensuing IgA response. These cells are innate immune cells which reside within the gut lamina 
propria as well as gut-associated lymphoid tissues (e.g. mesenteric lymph nodes). Hepworth et 
al. showed that in mice with deletions of MHCII on ILC3, the innate immune response to 
commensal bacteria was inadequately regulated and therefore resulted in proinflammatory CD4+ 
T cell responses proving that MHCII is the mechanism through which these cells interact [23]. 
ILC3s serve to downregulate TD B cell activation through MHCII-dependent interactions with 
CD4+ T cells, seeming to provide some regulation between adaptive and innate immune 
responses against commensals in order to maintain homeostasis [24]. MHCII has also been 
shown to be influential in controlling gut microbiota when expressed on dendritic cells, as it is vital 
for the presentation of antigens processed from commensal bacteria, which in turn drivers TH17 
cell differentiation [25].  
 The literature clearly demonstrates that MHCII is influential in regulating the composition 
of the gut microbiota. However, very little is known about the importance of MHCII expression on 
B cells in regulating microbiota composition and maintaining gut homeostasis. Here, using a 
RAG1-/- adoptive transfer model, we sought to address the hypothesis that B-cell-intrinsic MHCII 
antigen presentation significantly affects microbiota diversity. Results from our experiments 
demonstrate that, as expected, B-cell-intrinsic MHCII is required for germinal center formation in 
gut Peyer's patches, that B-cell-intrinsic MHCII facilitates the generation of high affinity anti-






Mouse models. A long-term breeding colony of WT, RAG1-/-, and MHCII-/- mice (all C57BL/6 
background) has been maintained by the Kubinak Lab at the University of South Carolina for three 
years. WT (Jax#000664), RAG1-/- (Jax#002216), and MHCII-/- (Jax#003584) mice were originally 
purchased from Jackson laboratories. All animals used in the experiments described here were 
derived from this colony. Male and female mice were used in all experiments. Mice were reared 
and maintained in a single environmentally controlled room exclusively used to house this mouse 
colony. Mice were maintained under constant environmental conditions (70oF, 50% relative 
humidity, 12:12 light:dark cycles) and were given ad libitum access to autoclaved drinking water 
and an irradiated soy-free mouse chow (Envigo; diet#2920X). All animal use strictly adhered to 
federal regulations and guidelines set forth by the University of South Carolina Institutional Animal 
Care and Use Committee (Protocol#101292).  
 
Flow Cytometry. Flow cytometry was performed on a BD Aria II cell sorter or BD Accuri C6 
cytometer. For cell staining, 500,000 cells per animal were stained with appropriate antibody 
cocktails. All antibodies were used at a final concentration of 1:250 with the exception of MHCII, 
which was stained at 1:500 concentration. Cells were stained in 100 L volumes in the dark for 
20 minutes. Stained cells were then washed twice with 1X wash buffer. Washed cells were fixed 
in 2% paraformaldehyde for 10 minutes and then analyzed on instrument. Purity of B and T cell 
isolations were determined by staining the spleen cells (after isolation) with CD4 and B220 
antibodies. Peyer’s Patches (PPs) were collected from the small intestines of mice, crushed and 
stained. There were two panels done on the PPs. Germinal center (GC) B cells and GC-T follicular 
helper cells (TFH). GC-B cells were identified as B220+IgDloFas+GL7+. GC-TFH cells were identified 




Adoptive B Cell Transfers. RAG1-/- mice were randomly assigned to treatment groups for B cell 
transfer experiments. Treatment groups received 1.0x107 B cells isolated from the spleens of sex 
and age-matched WT or MHCII-/- donors via magnetic purification using the EasySep Mouse 
CD19 Positive Selection Kit II (STEMCELL:  catalog # 18954). This kit obtains a cell purity of 98%. 
The treatment groups also received 1.0x105 T cells isolated from the spleens of the WT donors 
via magnetic purification using the EasySep Mouse Naïve CD4+ T Cell Isolation Kit (STEMCELL:  
catalog #19765A).  This kit obtains a cell purity of 98%. On day 0, B cells and T cells were 
administered via intraperitoneal injection (in 200uL volumes) and then animals were singly housed 
for ten weeks. At ten weeks post transfer, animals were sacrificed, and tissues were collected for 
analysis. For the second replicate, B cells and T cells were administered via intraperitoneal 
injection (in 200uL volumes) on day 0, and then animals were singly housed for seven weeks. At 
seven weeks post transfer, animals were sacrificed, and tissues were collected for analysis. 
Detection of fecal IgA was used as confirmation of successful B cell engraftment. A control group 
was done by administering isolated (age-matched) MHCII+ B or MHCII- B cells into RAG1-/- mice. 
The animals were singly housed for seven weeks after the B cells were administered via 
intraperitoneal injection. At seven weeks post transfer, animals were sacrificed, and tissues were 
collected for analysis. Based on these criteria, we determined that i.p. injection of donor B cells 
resulted in detectable fecal IgA in 100% of RAG1-/- recipient mice.   
 
Measurement of Fecal IgA. Longitudinal sampling of fecal pellets from experimental mice was 
performed to quantify the dynamics of IgA responses across adoptive transfer treatment groups. 
To do this, fecal pellets were collected immediately prior to adoptive transfer and then at weekly 
intervals. Fecal pellets were crushed in 500L of Hank’s Balanced Salt Solution and centrifuged 
at 4000x RCF for 10 minutes. Subsequently, the supernatant was transferred to new tubes and 
centrifuged at 8000 x RCF for 10 minutes. The remaining supernatant was collected. These 
samples were subsequently measured for IgA content by ELISA, using the Invitrogen IgA Mouse 
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Uncoated ELISA kit (catalog # 88-50450-88). The IgA content of these samples was determined, 
and the values for the groups of mice given MHCII+ and MHCII- B cells were corrected for noise 
by subtracting the standardized IgA concentration values generated from the control group 
samples. 
 
Measurement of IgA-bound bacteria. Pellets were collected from mice at the end of the 
experiment. Pellets were crushed and resuspended in 1 mL of 1X PBS and refrigerated for 20 
minutes. The samples were then homogenized and centrifuged. Supernatant was passed through 
a 100m strainer and centrifuged again. The pellets were resuspended in 1 mL of column buffer 
and centrifuged. The pellets were resuspended in 200L of column buffer and 4L of IgA antibody 
and 4L of Ig kappa light chain antibody were added to each sample. The stained samples were 
then covered and refrigerated for 30 minutes. The samples were then centrifuged and washed 
2X with 1XHBSS (without salts). The pellets were then resuspended in 200L of 1XHBSS and 
10L of 1X SYBR green was added to each sample. The samples were then covered and 
incubated at room temperature for 5 minutes. Fully stained samples were added to 2% PFA and 
1 mL of 1XHBSS.  
 
16S microbiota profiling. Fecal samples and small intestinal contents were collected from mice 
for 16S rRNA gene sequencing. For fecal samples, animals were scruffed and 1-2 fecal pellets 
were directly sampled from mice by having them defecate directly into a 1.5mL microfuge tube. 
All samples were frozen at -80oC until DNA extractions were performed. DNA was extracted using 
the QIAamp Powerfecal Pro DNA Isolation Kit (Qiagen) with 3 minute bead-beating step. Purified 
DNA was sent to University of Alabama Birmingham Heflin Center Genomics Core for 16S 
sequencing on an Illumina MiSeq. Raw fastq reads were de-multiplexed and forward and reverse 
primer sequences were trimmed from reads. This yielded a 251bp product spanning the V3/V4 
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region of the bacterial 16S rRNA gene. All 16S analyses were carried out using QIIME 2.0 analysis 
pipeline.  
 
Statistical Analysis.  
Data sets for all experiments represent pooled data from two to three experimental replicates 
(n=2-3 animals per replicate). For adoptive transfer experiments, animals were treated and then 
individually housed for the duration of experiments. Thus, each animal represents an independent 
replicate. Unless otherwise noted in figure captions, a Student’s t-test was used for significance 
testing with a Welch's correction applied for comparison between data sets with unequal variance. 







Adoptive transfer of WT B cells leads to higher levels of IgA production 
In order to test our hypothesis, transgenic RAG1-/- mice were randomly segregated into five 
experimental groups; four that were modified via adoptive transfer of immune cells and one control 
group that was given an injection of saline. The remaining four groups received the following 
adoptive transfer treatments; WT B cells only, MHCII- B cells only, WT T cells and MHCII+ B cells, 
or WT T cells and MHCII- B cells (Figure 1A). These mice had weekly ELISA quantification of 
fecal IgA performed, which yielded insights into the relative IgA concentration changes caused by 
MHCII presence on B cells and the role of T cells in generating antibodies. Mice who received 
WT B cells only (hatched blue line) produced relatively more IgA as compared to those which 
received MHCII- B cells only (hatched red line)(Figure 1B). The presence of T cells (solid blue 
line) did not cause significantly more IgA production relative to mice receiving only MHCII+ or 
MHCII- B cells (figure 1B). 
 
B-cell-intrinsic MHCII coordinates germinal center activity 
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 Flow cytometry gating of Peyer’s-patch-derived immune cells from control and 
experimental groups provided qualitative and quantitative evidence to suggest that B-cell intrinsic 
MHCII activity is crucial for the formation of germinal centers. Events were grouped into two 
primary groups: B220-CD4+, indicative of CD4+ T cells, and B220hiIgD+, indicative of B cells. T cell 
events were then gated by PD1 and CXCR5 markers – PD1loCXCR5lo events were classified as 
TFH cells; PD1hiCXCR5hi events were classified as germinal center TFH cells (GC-TFH). B cell 
events were segregated by B220hiIgDhi, categorized as naïve B cells, and B220+IgDlo events being 
categorized as activated B cells. Of the activated B cell population, FAS+GL7+ events were 
considered as germinal center B cells (figure 2A). The data indicates that as compared to mice 
which received MHCII- B cell and WT T cell adoptive transfers, those which received MHCII+ B 
cells and WT T cells maintained similar percentages of CD4+ T cells in Peyer’s patches, as 
compared to total lymphocytes. However, the group with WT B cells had significantly higher 
proportions of TFH cells and much higher proportions of GC-TFH cells (Figure 2B). Additionally, 
mice with WT B cells and WT T cells had significantly higher proportions of B cells as compared 
to all lymphocytes, higher proportions of activated B cells, and higher proportions of germinal 




B cell MHCII increases IgA-bacteria binding specificity  
 Fecal samples were collected and processed for flow cytometry to quantify the presence 
and abundance of IgA-bound bacteria. SYBR+ events were considered to represent bacteria, and 
these events were in turn gated on for IgA and Ig positivity. SYBR+IgA+Ig+ events were 
recognized as IgA-bound bacteria (figure 3A). The data shows that RAG1-/- mice receiving only 
MHCII+ B cells contain significantly higher percentages of IgA-coated bacteria within their feces 
as compared to RAG1-/- mice receiving only MHCII- B cells, and those RAG1-/- mice receiving WT 
T and MHCII+ B cells contained an even higher percentages of IgA-bound bacteria as compared 





B-cell-mediated mechanisms influence microbiota species diversity 
Microbiota composition was characterized by sequencing the bacterial 16S rRNA gene, and 
sequencing data was analyzed using the QIIME2.0 analysis pipeline. Unweighted UniFrac 
analysis demonstrated that between the experimental groups receiving WT T cells and either 
MHCII+ B or MHCII- B cells, no significant differences in phylogenetic diversity were observed 
(figure 4A). However, when the total number of species observed within these communities are 
compared, we observed that RAG1-/- mice receiving WT T and MHCI+ B cells maintained a 
significantly more species-rich microbial community as compared to RAG1-/- control mice (no 
cells) and RAG1-/- mice receiving WT T cells and MHCII- B cells (Figure 4B). Interestingly, RAG1-
/- mice with no adoptive transfer demonstrated higher levels of species diversity as compared to 





 The results of this study show that the presence of MHCII on B cells directs IgA-based 
responses which shape the composition of the microbiota. Through adoptive transfer models, 
quantitative evidence indicating that MHCII presence on B cells generates a significantly higher 
level of IgA secreted into the gut as compared to mice receiving MHC- B cells was generated. 
Additionally, the crucial role of B-cell-intrinsic MHCII in the promotion of germinal center formation 
in gut Peyer's patches and the resulting generation of high-affinity anti-commensal IgA responses 
was confirmed. MHCII-facilitated IgA responses to commensal microbiota were shown to be of 
higher affinity as compared to those induced through alternative pathways, and quantitative 
differences in this response were shown to be associated with levels of species diversity in the 
feces.   
 The data generated through ELISA quantifications of fecal IgA concentration clearly 
indicate the influential nature of B-cell-intrinsic MHCII in mucosal antibody secretion. Snider et. al 
previously reported that general MHCII ablation in the C2D strain of mice resulted in similar levels 
19 
 
of total IgA as measured by ELISA, suggesting that the presence of MHCII does not cause a 
change in total IgA production in feces, except in the situation of an immune response to a protein 
antigen[26]. While our study focuses on the effects of B-cell intrinsic MHCII on IgA production, 
MHCII presentation on other lymphocyte populations influences levels of IgA in the gut as well 
(e.g. dendritic cells and type 3 innate lymphoid cells) [27]. MHCII on dendritic cells is capable of 
presenting antigens to T cells, promoting their differentiation into regulatory T cells and TH17 cells, 
which have subsequent downstream effects on antibody production [28]. MHCII presentation on 
ILC3 is capable of stifling antibody-generating interactions between TFH cells and B cells; ablation 
of MHCII from ILC3s is associated with increased levels of IgA secretion [24]. MHCII on cells 
other than B cells is relevant to total IgA levels in the body, and results from the C2D model 
suggests that there are compensatory IgA-generating responses induced when MHCII is absent. 
Interestingly, the whole-body MHCII knockout model provides much context for the results 
observed in this experiment. By comparing IgA concentrations in the experimental groups which 
received MHCII+B cells and WT T cells, and those which have MHCII+ B cells and no T cells, we 
can affirm that TD antibody generation pathways do not generate a large fraction of the IgA 
secreted into the gut. However, we also observe that MHCII+ B cells do generate a significant 
amount of IgA in the gut relative to MHC- B cells (figure 1B). In some manner, MHCII on B cells 
is clearly relevant for IgA generation through TiD pathways; the mechanisms behind this 
phenomenon have not been described in the literature to our knowledge, and investigating these 
mechanisms is an excellent avenue for future inquiry. One interesting possibility is that B-cell-
intrinsic MHCII signaling may allow B cells to interact with an as-of-yet undefined CD4+ T cell 
subset that is able to develop in RAG1-/- mice. 
 The germinal center (GC) of the Peyer’s patch is a crucial micro-environment for high 
affinity immunoglobulin production in the intestine, and MHCII is highly influential in the signaling 
which influences the actions cells take within these environments [29]. Dendritic cell presentation 
of antigen to T cells is mediated through MHCII, and this interaction is crucial for maintaining 
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specificity in immune responses through differentiation of CD4+ T cells into regulatory T cells and 
TH17 cells [30].  These cells have been shown to regulate TFH secretion of IL-22 in the Peyer’s 
patch, subsequently leading to increased concentrations of IgA-producing plasma cells [31]. 
MHCII presentation of antigen on B cells is most crucial in governing the environment of the 
Peyer’s patch as well. Our data indicates that whilst MHCII presence on B cells does not 
drastically influence the percentage of CD4+ T cells in the Peyer’s patch, it certainly does influence 
the composition of these lymphocytes; a significantly higher percentage of TFH cells of total T cells 
is present in mice with WT B cells as compared to those without, and this trend is even more 
dramatically emphasized by the percentage of GC-TFH cells (figure 2B). This data affirms that 
MHCII+ B cells activate T cells to induce a germinal center response. Gating of the Peyer’s patch 
for B cell markers indicated that there was a higher percentage of B cells as a function of total 
lymphocytes in the population in MHCII+ B cell and WT T cell transfer groups, and a higher 
percentage of activated and GC-associated B cells. The relative abundance of B cells in the 
experimental group is likely caused by the formation of germinal centers, and the clonal 
proliferation of activated B cells forming in the germinal center reaction. The higher levels of 
activated B cells is also intrinsically related to MHCII presentation; B cell activation of T cells 
through MHCII-TCR interactions in turn leads to T cell secretion of factors which encourage the 
proliferation of the B cells into IgA producing plasma cells.   
 Whilst MHCII presence on B cells does increase the quantity of IgA secreted in the 
experimental groups of mice in this experiment, it is most importantly related to the quality, i.e. 
affinity, of the IgA secreted into the intestine. Flow cytometry of fecal bacteria determined that the 
highest percentages of IgA-bound bacteria were found in the experimental group with both WT T 
and MHCII+ B cells, and that the WT T and MHC- B cell transfer group had less than half the 
quantity of IgA-bound bacteria (figure 3B). Given this difference, MHCII on B cells must be 
important for generating high-affinity antibody responses to bacterial antigens. However, the 
experimental group receiving MHCII+ B cells only demonstrated very low levels of IgA binding to 
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bacteria despite having comparable concentrations of IgA in their gut, indicating that the TD-
antibody generation pathway is primarily responsible for elevating the quality of IgA secreted.  
High-affinity binding of IgA to the microbiota has been correlated to increased species 
diversity and gut health [31]. Therefore, we sought to determine if this phenomenon is occurring 
in our model and performed 16S rRNA gene sequencing to answer this question. Whilst general 
phylogenetic composition was not observed to be have been altered between RAG1-/- mice 
receiving either MHCII+ B and WT T cells, MHC- B and WT T cells, or control mice (i.e. no cells), 
the total numbers of species in the gut were shown to have been drastically altered by treatment 
method (figure 4). The most species diversity was observed in the RAG1-/- mouse cohort receiving 
WT T and MHCII+ B adoptive transfer model, indicative of the promoting effect of high-affinity IgA 
binding to bacteria on general gut microbiota diversity. The least species diversity was, 
interestingly, observed in the RAG1-/- cohort receiving WT T and MHCII- B cells. The IgA these 
mice secreted bound to a smaller percentage of bacteria and was evidently much less selective. 
MHCII has previously been described to be regulatory of T cell differentiation and proliferation, 
and ablation of MHCII has been associated with hyper-inflammatory responses in the gut related 
to the hypersecretion of cytokines by CD8+ T cells [32]. Do et al. demonstrated that RAG1-/- mice 
into which CD8+ T cells from MHCII-/- mice were adoptively transferred, developed colitis. Previous 
studies have shown a strong correlation between decreased microbiota diversity and 
inflammatory bowel disease [33]. This information provides a clear framework on which to view 
our results; in our WT T and MHCII- B cell model, lack of regulation from B cells may be inducing 
hyperactive T cell responses which resulted in gut inflammation and subsequent dysregulation of 
the microbiota, which may be responsible for the decreased species number we observe in these 
animals.  
 The connection between our gut microbiome’s composition and its effects on our health 
has been increasingly examined in the past decade. The composition of the microbiome has been 
shown to effect human disease, and vice versa. One of the primary measures through which 
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scientists have been able to quantify the quality of the microbiota to examine this phenomenon is 
through study of species diversity, frequently using 16S rRNA gene sequencing. With this tool, 
the number and phylogeny of bacterial species in a fecal sample can be determined. Species 
number and diversity have been positively correlated to good health outcomes. Frank et al. wrote 
of the connection of microbiota species diversity to common bowel diseases in humans, such as 
ulcerative colitis, and Crohn’s disease. The authors found that in human subjects, these intestinal 
diseases were strongly correlated with decreased numbers of both total bacteria present in the 
gut and number of species present in the gut, and dysbiosis in terms of groups of bacteria such 
as Bacillus were overrepresented relative to the gut community of healthy individuals [34]. The 
composition of the microbiome is bi-directionally related to the immune processes which influence 
it; bacterial metabolic byproducts, like butyrate released by Clostridia, leads to regulatory T cell 
differentiation and induction of tolerant immune responses against the microbiota [35]. Specific 
bacterial species have also been linked with activation of immune responses; segmented 
filamentous bacteria, a species which grows in close association with the mucosa, has been 
shown to induce CD4+ T cell differentiation into TH17 cells, which in turn produce interleukins 
which regulate T cell activation [36]. A wide variety of bacteria function in tandem to regulate the 
composition of the microbiota and preserve homeostasis within the gut, thereby promoting host 
health. Therefore, upkeep of microbiota diversity is highly important.  
 Through promotion of germinal center activity, MHCII on B cells is highly important to 
regulating the quantity and quality of the IgA response to commensal bacterial in the gut. By 
allowing the formation of the germinal center, B cells promote high-affinity TD IgA responses in 
the gut. We have demonstrated that these said responses lead to high-affinity IgA binding of 
commensal bacteria, which can regulate the composition of the microbiota through various 
pathways, including controlling bacterial virulence and downstream effects on T cell activation. 
Thereby, we have determined that B-cell-intrinsic MHCII signaling leads to a more diverse 
microbiota, a characteristic associated with health and wellness in humans and mice alike. Our 
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adoptive transfer model both answers the question of the value of B-cell-intrinsic MHCII signaling 
in controlling the gut microbiota through TD IgA antibody secretion, but also suggests that B-cell-
intrinsic MHCII may be playing a currently unappreciated role in T-cell-independent IgA production 
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